VTE in patients undergoing total knee arthroplasty (TKA)
CRSPCRISPR TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for SRSD107 in VTE in patients undergoing total knee arthroplasty (TKA). The expected timing is based on the latest available company guidance and may change.
Co-developed w/ Sirius Tx. 9/22/25- First participant dosed. 11/10/25:- Phase 2 trial of SRSD107 in prevention of venous thromboembolism after total knee arthroplasty has dosed its first patient in Europe, is ongoing, and has been expanded to additional centers in Europe, with results intended to inform dose selection for future pivotal trials. 01/12/26:- Ongoing Ph2 CTX611/SRSD107 TKA trial; top-line VTE prevention data in H2 2026. 02/12/26:- CTX611 Ph2 TKA trial ongoing; update expected H2 2026; CRISPR to lead global Ph3 development with Sirius. 05/04/26:- CTX611 Ph2 TKA trial progress reiterated; update on FXI siRNA program still expected in H2 2026. 08/03/26:- CTX611/SRSD107 Ph2 TKA update expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.